Sophia N. Karagiannis
King's College London, United Kingdom
- Orcid: 0000-0002-4100-7810
- Publications: N/A
- Citations: N/A
- Keywords: B cells, antibodies, cancer immunology, cancer immunotherapy, IgE, IgG, immune effector cells, Fc receptors, monocytes, macrophages, NK cells, melanoma, ovarian cancer, breast cancer, triple-negative breast cancer, humoral response
Short Bio
- Sophia Karagiannis is Professor of Translational Cancer Immunology and Immunotherapy at St. John’s Institute of Dermatology, King's College London, United Kingdom. She is a translational cancer immunologist with experience in B cell immunology, antibody engineering and bench-to-clinic therapeutics translation in academic, biopharmaceutical and biotech environments (USA, Rutgers University; UK, SmithKline Beecham/GlaxoSmithKline, Cambridge-based Adprotech Ltd). Prof. Karagiannis heads a cancer antibody discovery team at King’s College London focused on the crosstalk between human immunity, inflammation and cancer and on the design of novel therapeutic antibodies for melanoma, ovarian and breast cancers. Key areas of research in the Karagiannis group centre on the study of patient-derived B cells and antibodies, Fc-engineered antibodies of different isotypes and antibody-drug conjugates for the treatment of solid tumours. Her group is the first to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. She is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based anti-cancer agents.
